{name}
{subtitle}
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
city
~18 mi. (Szeged, Hungary, +130 more cities)
facility
Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ-Urológiai Klinika ( Site 1303)
drug
BCG solution, +1 more drug
Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)
city
~18 mi. (Szeged, Hungary, +137 more cities)
facility
Szegedi Tudomanyegyetem ( Site 0504)
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
city
~18 mi. (Szeged, Hungary, +201 more cities)
facility
Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont /ID# 221705
drug
azacitidine, +1 more drug
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)
city
~18 mi. (Szeged, Hungary, +28 more cities)
facility
Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont /ID# 219172
biomarker
IGH-CCND1 Fusion, +1 more biomarker
drug
carfilzomib, +2 more drugs
drug type
chemotherapy, +2 more types
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis
city
~77 mi. (Novi Sad, Serbia, +165 more cities)
facility
Clinical Center Vojvodina /ID# 230853
biomarker
del(11)(q10), +27 more biomarkers
drug
navitoclax, +1 more drug
A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm
city
~77 mi. (Novi Sad, Serbia, +42 more cities)
facility
Clinical Center Vojvodina /ID# 240107
condition
Chronic Myelomonocytic Leukemia, +3 more conditions
drug
celecoxib, +2 more drugs
drug type
Other, +1 more type
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
city
~81 mi. (Kecskemét, Hungary, +144 more cities)
facility
Bacs-Kiskun Megyei Korhaz-Onkoradiologiai Kozpont ( Site 2308)
drug
belzutifan, +3 more drugs
drug type
immunotherapy, +1 more type
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
city
~81 mi. (Kecskemét, Hungary, +226 more cities)
facility
Bacs-Kiskun Megyei Korhaz-Onkoradiologiai Kozpont ( Site 1321)
drug
enzalutamide, +1 more drug
drug type
hormone therapy, +1 more type
Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
city
~81 mi. (Kecskemét, Hungary, +199 more cities)
facility
Bacs-Kiskun Megyei Korhaz-Onkoradiologiai Kozpont ( Site 0483)
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
city
~81 mi. (Kecskemét, Hungary, +207 more cities)
facility
Bacs-Kiskun Megyei Korhaz ( Site 2913)
biomarker
ER Positive, +1 more biomarker
drug
cyclophosphamide, +6 more drugs
drug type
chemotherapy, +3 more types
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
city
~81 mi. (Timişoara, Romania, +158 more cities)
facility
Policlinica Oncomed SRL ( Site 2504)
drug
olaparib, +4 more drugs
drug type
chemotherapy, +3 more types